Rawan Mohammad Al Saudi1, Violet Kasabri2, Randa Naffa3, Nailya Bulatova1, Yasser Bustanji1. 1. School of Pharmacy, The University of Jordan, Queen Rania Street, Amman, Jordan. 2. School of Pharmacy, The University of Jordan, Queen Rania Street, Amman 11942, Jordan. 3. School of Medicine, The University of Jordan, Queen Rania Street, Amman, Jordan.
Abstract
BACKGROUND: The aim of the study was to compare and correlate glycated high-density lipoprotein (GHDL-C) and glycated low-density lipoprotein (GLDL-C) plasma levels with adiposity indices [weight/hip ratio (WHR) and body adiposity index (BAI)], lipid ratios and hematological indices [platelet/lymphocyte ratio (PLR), monocyte/lymphocyte ratio (MLR)]. METHODS: This was a cross-sectional study of 30 nondiabetic metabolic syndrome (MetS) patients, 30 prediabetic or type 2 diabetes mellitus (T2DM) patients and 30 normoglycemic controls. RESULTS: Remarkably both GHDL-C and GLDL-C levels lacked any intergroup statistically significant discrepancy in either MetS or MetS-pre/T2DM versus control (p > 0.05). Unlike GLDL-C/LDL-C ratios for either MetS groups; there were highly significant intergroup differences in the means of GHDL-C/HDL-C ratios when comparing both nondiabetic MetS and MetS-pre/T2DM groups versus controls (p = 0.001). In MetS patients; GHDL-C and GLDL-C proportionally correlated with WHR (p < 0.05). Also, MetS GHDL-C correlated inversely with MLR and monocytes (p < 0.05). In MetS-pre/T2DM; GLDL-C directly correlated with BAI, platelet count and PLR (p < 0.05). CONCLUSION: GLDL-C and GHDL-C are dysfunctional glucolipotoxicity lipoproteins and may present putatively surrogate biomarkers for prediction/prevention of metabolic disturbances.
BACKGROUND: The aim of the study was to compare and correlate glycated high-density lipoprotein (GHDL-C) and glycated low-density lipoprotein (GLDL-C) plasma levels with adiposity indices [weight/hip ratio (WHR) and body adiposity index (BAI)], lipid ratios and hematological indices [platelet/lymphocyte ratio (PLR), monocyte/lymphocyte ratio (MLR)]. METHODS: This was a cross-sectional study of 30 nondiabetic metabolic syndrome (MetS) patients, 30 prediabetic or type 2 diabetes mellitus (T2DM) patients and 30 normoglycemic controls. RESULTS: Remarkably both GHDL-C and GLDL-C levels lacked any intergroup statistically significant discrepancy in either MetS or MetS-pre/T2DM versus control (p > 0.05). Unlike GLDL-C/LDL-C ratios for either MetS groups; there were highly significant intergroup differences in the means of GHDL-C/HDL-C ratios when comparing both nondiabetic MetS and MetS-pre/T2DM groups versus controls (p = 0.001). In MetS patients; GHDL-C and GLDL-C proportionally correlated with WHR (p < 0.05). Also, MetS GHDL-C correlated inversely with MLR and monocytes (p < 0.05). In MetS-pre/T2DM; GLDL-C directly correlated with BAI, platelet count and PLR (p < 0.05). CONCLUSION: GLDL-C and GHDL-C are dysfunctional glucolipotoxicity lipoproteins and may present putatively surrogate biomarkers for prediction/prevention of metabolic disturbances.
Authors: F Galland; L Duvillard; J M Petit; L Lagrost; G Vaillant; J M Brun; P Gambert; B Vergès Journal: Diabetes Metab Date: 2006-12 Impact factor: 6.041
Authors: Ahmet Kaya; Mustafa Kurt; Ibrahim Halil Tanboga; Turgay Işık; Zeki Yüksel Günaydın; Yasemin Kaya; Selim Topçu; Serdar Sevimli Journal: Clin Appl Thromb Hemost Date: 2013-01-23 Impact factor: 2.389
Authors: Maria Notarnicola; Maria Gabriella Caruso; Valeria Tutino; Valentina De Nunzio; Isabella Gigante; Giampiero De Leonardis; Nicola Veronese; Ornella Rotolo; Rosa Reddavide; Elisa Stasi; Chiara Miraglia; Antonio Nouvenne; Tiziana Meschi; Gian Luigi De' Angelis; Francesco Di Mario; Gioacchino Leandro Journal: Acta Biomed Date: 2018-12-17
Authors: Muhammad Shoaib Khan; Muhammad Ishaq; Muhammad Talha Ayub; Ateeq U Rehman; John J Hayes; Mohammad Mortada; Robert W W Biederman Journal: J Lipids Date: 2021-01-12